| Epicept: Good Play in Light of Recent Developments VFC submits: Epicept Corporation (EPCT) announced on Tuesday that the European Medicines Agency [EMA] considers the company's post-approval commitments for Ceplene fulfilled. Originally the agency had required Epicept to conduct an additional confirmatory Phase III trial evaluating Ceplene with low-dose interleukin-2 (IL-2) versus a comparator arm of either no treatment or IL-2 alone, but the EMA ultimately agreed with a panel put together to assess the situation and decided that such a trial was not feasible. Epicept continues to enroll patients for a separate ongoing post-approval trial with an estimated completion date of sometime in 2011. Complete Story » seekingalpha.com |
Health Officials Ask for Hospital Probe State health officials have asked the attorney general's office to investigate the actions of trustees at two hospitals and a nonprofit health network linked to an influence-peddling scandal that sent a former Queens assemblyman to prison. online.wsj.com |
Judge Holds Off on Lovenox Decision A federal judge held off a decision on whether to bar a generic version of Sanofi-Aventis SA's big-selling drug Lovenox, in a lengthy court hearing that highlighted the stakes for a new generation of copycat drugs. online.wsj.com |
Genomic Health to Present at Two Upcoming Investor Conferences [PR Newswire] - Genomic Health, Inc. today announced that members of its management team will present at the following conferences in September: us.rd.yahoo.com |
Stent-Graft Study Points to Oversight Gap An unusually high percentage of the participants in a clinical trial for an aortic-aneurysm treatment known as a stent-graft, developed blood clots. online.wsj.com |